Permeon Biologics

Permeon Biologics, Inc.
private
Industry Health care
Biotechnology
Founded 2011
Founder David R. Liu
Headquarters Cambridge, Massachusetts, United States
Key people
 John Ripple
Noubar Afeyan
Products Intraphilin™ Technology Platform
Website permeonbio.com

Permeon Biologics, Inc. is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2011 by Harvard chemist David R. Liu and Noubar Afeyan, CEO of Flagship Ventures, the company’s develops a class of proteins, under the trademark Intraphilin™, that enable the transport of large molecules such as antibodies into cells, thereby potentially enabling new classes of intracellular therapies.[1][2]

Ownership

Permeon Biologics closed a Series A financing in November, 2010, with Flagship Ventures of Cambridge, Massachusetts, and ARCH Venture Partners of Chicago.[3]

References

  1. ↑ Brian Gormley, "Flagship Ventures Hatches Two More Health-Care Companies", The Wall Street Journal (March 17, 2011)
  2. ↑ James J. Cronican, Kevin T. Beier, Tina N. Davis, Jen-Chieh Tseng, Weida Li, David B. Thompson, Allen F. Shih, Erin M. May, Constance L. Cepko, Andrew L. Kung, Qiao Zhou, and David R. Liu "A Class of Human Proteins That Deliver Functional Proteins Into Mammalian Cells In Vitro and In Vivo", Chem Biol, 2011 July 29, 18(7), 833–838
  3. ↑ Permeon Biologics, "Investors"